The Ovarian Cancer Research Alliance (OCRA) 2027 Health Equity Research Grant (HEG) — first launched in 2024 with sponsorship from GSK — provides $200,000 over two years ($100,000/year) to investigators tackling disparities in ovarian and gynecologic cancer care. This grant is specifically designed to fund projects that examine the social, economic, cultural, racial, ethnic, and/or geographic factors that drive inequities in ovarian cancer diagnosis, treatment, and survival outcomes for underserved communities. It is open to investigators at all career levels at accredited academic and non-profit research institutions worldwide. The LOI deadline for the 2027 cycle is March 25, 2026. OCRA may continue to partner with industry sponsors like GSK for this grant, which may entail sharing progress reports with the sponsor. All applications are submitted via SmartSimple.
Eligibility Criteria:
- Principal Investigator must hold an MD or PhD at the time of LOI submission
- Open to investigators at all career stages
- No citizenship or residency restrictions; international applicants are eligible
- Research must focus on ovarian cancer and/or related gynecologic cancers with a health equity angle
- Projects that examine racial, ethnic, socioeconomic, geographic, or genetic disparities in diagnosis, treatment, or outcomes are prioritized
- If the grant is industry-sponsored, progress reports will be shared with the industry partner
- PI may hold only one active OCRA grant at a time; only one LOI per cycle per PI
Funding Details:
- Award amount: $200,000 over two years ($100,000/year)
- Budget may include personnel, supplies, travel, and other direct costs; subcontracts are permitted
- 10% indirect costs allowed
- Full proposal deadline (by invitation): June 10, 2026
- Award notifications: End of September 2026
- Funded projects start: early 2027
Deadline:
- Letter of Intent (LOI): March 25, 2026
- LOI notifications (invite to full proposal): Mid-May 2026
- Full Proposal Deadline (invited only): June 10, 2026
- Award notifications: End of September 2026
- All submissions via SmartSimple
Contact / Further Information: